Clinical trial
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
NCT02252172 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 16, 2015
- Completion date
- October 2, 2024
- Enrollment
- 737 (actual)
- Sites
- 206
Conditions
As the registry lists them; a condition with its own page is linked.